Company / R&D per Share
Praxis Precision Medicines, Inc. R&D per Share History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$13.75
FY2025
5-year range
$2.83 / $50.45
FY2021-FY2025
Trend
-20.7%
vs FY2024
Sector context
#10 of 208
Health Care
What the data says
Among 208 Health Care companies, Praxis Precision Medicines, Inc. is in the top 5% for r&d per share. R&D per Share has declined for 3 consecutive years, from $50.45 in FY2022 to $13.75 in FY2025.
Based on SEC 10-K filings.
13.75 in FY2025 with a 5-year CAGR of +22.3%. Top quartile in the Health Care sector.
Declined from $26.36 to $13.75 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -35.2%
- 5-Year CAGR
- +22.3%
- 10-Year CAGR
- -
Sector benchmark
Top 5% in Health CareTop 5% of 208This company $13.75 Sector average $28.82
▼
-52.3% below sector average
Key checks
Key Insights
- Praxis Precision Medicines, Inc.'s r&d per share has declined for 3 consecutive years.
- In FY2025, r&d per share decreased 20.7% year-over-year.
- Ranks #10 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 4.48 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.75 | -20.7% |
| FY2024 | $17.34 | -34.2% |
| FY2023 | $26.36 | -47.8% |
| FY2022 | $50.45 | +1681.0% |
| FY2021 | $2.83 | -43.6% |
| FY2020 | $5.03 | -74.0% |
| FY2019 | $19.32 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026